Document Detail


Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers.
MedLine Citation:
PMID:  19954717     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A randomized, two-way, crossover, bioequivalence study in 32 fasting, healthy, male volunteers was conducted to compare two brands of clopidogrel 75 mg tablets, Thrombo (EIPICO, Egypt) as test and Plavix (Sanofi Pharma/Bristol-Myers Squibb, Paris, France) as reference. The study was performed in a Pharmaceutical Research Unit (PRU) using HPLC/ MS-MS. Arithmetic means for clopidogrel test versus reference formulation, respectively were for Cmax (4.39 +/- 2.58 vs. 4.30 +/- 2.65) ng/ml, AUC0-t (11.98 +/- 9.82 vs. 12.01 +/- 9.46) ng.h/ml, AUC0- yen (12.43 +/- 9.94 vs. 12.49 +/- 9.58) ng.h/ml, t1/2 (6.06 +/- 3.87 vs. 5.87 +/- 2.47) h and the medians for tmax (1 h vs. 0.75 h). Arithmetic means for clopidogrel carboxylic acid metabolite were Cmax (3.75 +/- 1.19 vs. 3.51 +/- 0.97) microg/ml AUC0-t (9.18 +/- 2.36 vs. 9.17 +/- 2.06) microg.h/ml, AUC0- yen (9.72 +/- 2.4 vs. 9.80 +/- 2.21) microg.h/ml , and t1/2 (6.43 +/- 3.52 vs. 6.33 +/- 1.71) h for test versus reference formulation respectively and there was no difference in the medians for tmax (0.75 h). The parametric 90% confidence intervals for the mean of the difference between log-transformed values were within the accepted range for bioequivalence of 80 - 125% as proposed by the US-FDA , namely for clopidogrel (90.66% - 109.66%), (90.63% - 109.73%), and (93.19% - 115.37%) for AUC0-t, AUC0- yen, and Cmax, respectively and also for clopidogrel carboxylic acid metabolite (94.90 - 104.19) , (94.04 - 103.86) and (96.47 - 114.79) for AUC0-t , AUC0- yen, and Cmax, respectively. Thus there was no significant difference between these values and therefore the two products can be considered bioequivalent.
Authors:
O El Ahmady; M Ibrahim; A M Hussein; R T Bustami
Related Documents :
12493057 - A systematic review of the accuracy of ultrasound in the diagnosis of endometriosis.
8241377 - Where is the likelihood ratio test powerful for detecting two component normal mixtures?
11299817 - Serum ceruloplasmin in melanoma patients.
17240657 - The analysis of stratified 2 x 2 contingency tables.
16956457 - The utility of the true test in a private practice setting.
21897317 - High-frequency skull vibration-induced nystagmus test in partial vestibular lesions.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  47     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-03     Completed Date:  2010-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  780-4     Citation Subset:  IM    
Affiliation:
Egyptian International Pharmaceutical Industries Company, Cairo, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Humans
Male
Platelet Aggregation Inhibitors / administration & dosage,  pharmacokinetics*
Tablets
Therapeutic Equivalency
Ticlopidine / administration & dosage,  adverse effects,  analogs & derivatives*,  pharmacokinetics
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Tablets; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equiva...
Next Document:  Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled par...